ChromaDex (CDXC) Announces Thorne Research Loses Patent Litigation
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- SK Hynix’s record plunge drags down global chip stocks
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
Thorne Research, Inc. Loses Patent Challenge Decision, Upholding ChromaDex’s Intellectual Property Held Under Exclusive License From Dartmouth College
August 15, 2022 6:34 AM EDTThe 807 patent held under exclusive license covers compositions comprising NAD+ precursor nicotinamide riboside
LOS ANGELES--(BUSINESS WIRE)-- ChromaDex Corp. (NASDAQ: CDXC) (the Company) a global bioscience company dedicated to healthy aging, announced the U.S. Patent & Trademark Offices Patent Trial and Appeal Boards (PTAB) decision to reject Thorne Research, Inc. attempt to invalidate U.S. Patent No. 8,197,807 (the 807 patent). ChromaDex holds an exclusive license to the 807 patent for compositions including nicotinamide riboside (NR) from the Trustees of Dartmouth College. The decision, if upheld upon appeal, precludes Thorne Research, Inc. from... More
